Efficacy of Alkaline Phosphatase in Critically Ill Patients with COVID-19: A Multicentre Investigator-Initiated Double-Blind Randomised Placebo-Controlled Trial.
Anouk PijpeStephan G PapendorpJoost W van der HeijdenBen VerminIris ErtugrulMichael W J RittBjorn StesselIna CallebautAlbertus BeishuizenMarcel VligJoost JimminkHenk J HuijgenPaul P M van ZuijlenEsther MiddelkoopEvelien de JongPublished in: Biomedicines (2024)
Alkaline phosphatase (AP) therapy in COVID-19 ICU patients showed no significant benefits in this trial.
Keyphrases
- double blind
- study protocol
- clinical trial
- placebo controlled
- phase iii
- end stage renal disease
- phase ii
- coronavirus disease
- sars cov
- ejection fraction
- newly diagnosed
- randomized controlled trial
- open label
- peritoneal dialysis
- prognostic factors
- stem cells
- patient reported outcomes
- cross sectional
- bone marrow
- mesenchymal stem cells
- acute respiratory distress syndrome
- mechanical ventilation
- smoking cessation